Rheumatoid arthritis - etanercept and infliximab (Partially replaced by TA130)

The guidance on the use of etanercept and infliximab after the failure of conventional DMARDs has been replaced by Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130). The guidance in TA36 on the use of etanercept and infliximab after the failure of another TNF -i ...

Read the complete summary

The guidance on the use of etanercept and infliximab after the failure of conventional DMARDs has been replaced by Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130). The guidance in TA36 on the use of etanercept and infliximab after the failure of another TNF -inhibitor remains in place, and is currently subject to a review of Adalimumab, etanercept, infliximab, abatacept and rituximab for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor.

hide